Here, we found that the levels of TPT1 within the tumor significantly correlated with the response to anti-PD-L1 therapy and survival in cancer patients, indicating that the expression status of TPT1 may serve as a marker to predict the clinical outcomes of anti-PD-L1 therapy. Here, CD274 is linked to cancer.